|
|||||||||||||||
|
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016 Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI) |
||||||||||||||
Issue: May 2024
Volume 9 | Issue 5
Review Result and Publication of Paper within : 2-3 days
Click Here For more DetailsFor Authors
Forms / Download
Published Issue Details
Editorial Board
Other IMP Links
Facts & Figure
Impact Factor : 8.76
Issue per Year : 12
Volume Published : 9
Issue Published : 96
Article Submitted :
Article Published :
Total Authors :
Total Reviewer :
Total Countries :
Indexing Partner
Join RMS/Earn 300
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
Published Paper Details
|
|
| Paper Title: | Clinical overview of Deferasirox Ion Chelation Theropy |
| Authors Name: | Divya Diliprao Deshmukh , Aarti Nivas Patil , Rushikesh Janik Divate |
| Download E-Certificate: | Download |
| Author Reg. ID: |
IJNRD_194499
|
| Published Paper Id: | IJNRD2305243 |
| Published In: | Volume 8 Issue 5, May-2023 |
| DOI: | |
| Abstract: | Deferasirox, an oral iron chelator that is given once daily, is often used in the treatment of people with transfusional hemosiderosis. In several Phase II trials and their respective extension studies, as well as a Phase III trial, the effectiveness and safety of this novel agent in transfusion-dependent patients with -thalassemia, sickle cell disease, and bone marrow failure syndromes, including myelodysplastic syndrome and aplastic anemia, have been established. According to evidence from several clinical trials, a deferasirox dose of 20 mg/kg/day stabilises serum ferritin levels and liver iron concentration, while a dose of 30-40 mg/kg/day reduces these values and causes negative iron balance in red cell transfusion-dependent patients with iron overload. In multiple important clinical trials, deferasirox was well tolerated, with the most common side effects being gastrointestinal issues, skin rashes, non-progressive blood creatinine rises, and elevations in liver enzyme levels. Longer-term extension studies have also demonstrated the efficacy and safety of deferasirox. Patients taking deferasirox therapy must be routinely observed to ensure quick treatment for any side effects that may develop with long-term medication. |
| Keywords: | Deferasirox, iron overload, thalassemia, sickle cell disease, and myelodysplastic syndrome are some of the terms that may be used. |
| Cite Article: | "Clinical overview of Deferasirox Ion Chelation Theropy", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.8, Issue 5, page no.c316-c325, May-2023, Available :http://www.ijnrd.org/papers/IJNRD2305243.pdf |
| Downloads: | 000118754 |
| ISSN: |
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016 An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator |
| Publication Details: |
Published Paper ID:IJNRD2305243 Registration ID: 194499 Published In: Volume 8 Issue 5, May-2023 DOI (Digital Object Identifier): Page No: c316-c325 Country: Jalna, Maharashtra, India Research Area: Pharmacy Publisher : IJ Publication Published Paper URL : https://www.ijnrd.org/viewpaperforall?paper=IJNRD2305243 Published Paper PDF: https://www.ijnrd.org/papers/IJNRD2305243 |
| Share Article: |
|
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijnrd.org
| Semantic Scholar | Microsaoft Academic | ORCID | Zenodo |
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | PUBLON |
| DRJI | SSRN | Scribd | DocStoc |
ISSN Details
 |
 |
|
ISSN: 2456-4184
Impact Factor: 8.76 and ISSN APPROVED
Journal Starting Year (ESTD) : 2016
DOI (A digital object identifier)
Conference
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Important Details
Social Media
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Join RMS/Earn 300
| Copyright © 2024 - All Rights Reserved - IJNRD |
Facebook Twitter Instagram LinkedIn